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Short-term in vitro genetic toxicity assays have not fulfilled their anticipated role in predicting the carcinogenicity of environmental agents reliably and
economically. A redirection in emphasis from nonanimal systems to relevant animal assays and population monitoring will help to reestablish the
credibility of this field. An analysis of the various steps in the carcinogenic process indicates the biological responses occurring during these stages
can be utilized for early detection of environmental carcinogens. Emphasis should be placed on using the earliest significant response that indicates
genetic damage (e.g., gene mutations and chromosome alterations). Assays that detect pregenomic damage (e.g., adduct formation), without evi-
dence of subsequent heritable genetic alterations, may produce misleading results for risk assessment and should not be considered as stand-alone
monitoring procedures. Late biological responses may occur in tissues or organs where genetic damage may be difficult to measure, and the oppor-
tunity for intervention diminishes as we approach the clinical outcome. For example, analyzing localized cells that contain activated protooncogenes
and inactivated tumor suppressor genes, although they further document adverse response from exposure to carcinogens, may be of greater value
for indicating clinical outcome than for genetic monitoring. With few notable exceptions, the window of opportunity for genetic monitoring is the
period after exposure where genetic damage is evident and where circulating lymphocytes can faithfully record this damage. An ongoing study of
butadiene-exposed workers illustrates an optimum protocol, where multiple assays can be carried out and correlated with both external and internal
measurements of exposure. Population monitoring studies integrating the total effects of multiple chemical exposure are especially suited for moni-
toring communities near waste disposal sites or industrial plants. Studies to date indicate that these procedures are sufficiently sensitive to detect
low-level chronic exposure to genotoxic chemicals.-Environ Health Perspect 102(Suppl 9):125-132 (1994)
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Introduction
A requisite for the survival of living forms
is the ability to continually adapt and
change. Since the beginning of the indus-
trial revolution, organisms, including
humans, have been required to adapt to a
large number of new man-made chemicals
in their environments. We are challenged
to cope, not with discreet pure chemicals,
but with various mixtures ofchemicals and
the products oftheir interactions. Our abil-
ity to respond and change is far from per-
fect, and even the very process of
adaptation may lead, in some individuals,
to adverse health outcomes. One basic
form of adaptation to xenobiotic exposure
is induction of enzyme systems that are
involved in metabolism and detoxification
(1). The attempt to detoxify xenobiotics
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frequently leads to the formation of elec-
trophiles that interact with and alter DNA,
thus setting in motion the complex, multi-
stage process that is associated with cancer
(Figure 1). A more complete understanding
of the roles of genetically toxic agents in
the complex process of carcinogenesis
requires that genetic toxicology studies
address the issues ofmetabolism and phar-
macokinetics and that a broad spectrum of
genetic events be detectable. This means
that in vivo studies in appropriate animal
systems should be used, and that relevant
exposure conditions need to be evaluated.
When feasible, studies of exposed human
populations should be conducted. in vitro
assays are of greatest value when they are
used to examine the effects of specific
metabolites or when mechanisms of geno-
toxicity of known proximate mutagens are
to be determined.
To detect, and consequently reduce or
eliminate our exposure to carcinogens, a
number ofcomplementary in vivo genotoxi-
city test procedures should be employed.
Laboratory animals can be used as surrogates
for humans, but human studies should be
carried out whenever there are known expo-
sures to potential mutagens and carcinogens.
The need for human genetic monitoring is
underscored by recognition of the differ-
ences in response between human and
experimental animals, the potential for
interactive effects from exposure to multiple
chemicals, and limitations of cancer epi-
demiologic studies. A better understanding
ofthe various stages in the multistep process
that leads to cancer underscores the impor-
tance ofearly detection ofgenetic alterations
that result from exposure to carcinogens. In
this paper we will describe biological moni-
toring techniques as they relate to the vari-
ous stages in the neoplastic process.
Specifically we will indicate: a) those proce-
dures offering the maximum opportunity
for identifying carcinogenic exposure, b)
limitations of these procedures, c) the limi-
tations ofclassical epidemiologic studies, d)
an example of an integrated genetic moni-
toring protocol (a current study of 1,3-buta-
diene), and e) an appropriate application of
genetic monitoring assays.
Attributes of a Complete
Carcinogen
A carcinogen, by definition, can transform
normal cells to cancerous cells. As depicted
in Figure 1, a complete carcinogen can
induce the following detectable events:
a) induces the initial genetic change leading
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Figure 1. Processes and factors involved in the transformation of normal cells to cancerous cells.
to an initiated cell, b) may generate reactive
oxygen species that cause further genetic
alterations, c) produces further genetic
alterations in the initiated cell leading to
additional genetic damage, including onco-
gene activation and/or tumor suppressor
gene inactivation, d) enhances clonal
expansion ofthe initiated cell (promotion)
and/or accelerates cell proliferation, and e)
may modify immune responses. Some
chemicals are active during some of the
stages in this process that occur after cell
initiation, thus increasing cell proliferation
and enhancing the effect of the initial
genetic lesion; but it is only a complete car-
cinogen that can influence all of the steps
that lead to cancer. Given the biological
attributes required of a complete carcino-
gen, it is understandable why we have
found very few chemicals that are complete
carcinogens. Since a complete carcinogen
influences the various steps in the contin-
uum that lead from initial genetic lesion to
cancer, it follows that biological monitor-
ing could be performed at any stage in this
process. Before examining the various tech-
niques available for monitoring the effects
ofa complete carcinogen, it may be worth-
while to discuss the concept of non-geno-
toxic carcinogens.
Nongenotoxic Carcinogens
Weisburger and Williams (2-4), have pro-
posed the existence of a novel class of
atypical, epigenetic or nongenotoxic carci-
nogens. Nongenotoxic carcinogens have
been defined operationally as those chemi-
cals that lack genotoxicity as their primary
biological action, but yield genotoxic
events as a secondary result of other types
ofactivity, such as forced or accelerated cell
proliferation. These chemicals do not react
directly with DNA (5). Since non-geno-
toxic chemicals may be an important cate-
gory of cancer-causing agents and they
require attention different from genotoxic
carcinogens, compounds should not be
placed in this category until their complete
mechanism of action is clearly established.
Every attempt should be made to minimize
describing chemicals as non-genotoxic sim-
ply because of incomplete, insufficient, or
inappropriate testing. Ashby has correctly
stated, "It is important to emphasize that
nongenotoxic carcinogenic mechanisms
will probably have a definable genetic basis
when they are understood" (J. Ashby, per-
sonal communication) At the present time,
dioxin (TCDD) is considered a prime
example ofa nongenotoxic carcinogen (5).
TCDD is among the most potent chemical
carcinogens that have been identified. This
chemical is carcinogenic in many species at
many sites. Its tumor-promoting, hormon-
ally related activity has been well studied
and characterized. However, this proposed
epigenetic mechanism of TCDD-induced
carcinogenesis does not account for the
many relatively rare types of TCDD-
induced tumors and other phenomena
exhibited by this chemical. (6,7). It is
interesting to note that although this chem-
ical has been extensively studied, an in vivo
gene mutation assay after subacute or
chronic exposure has yet to be reported. It
may well be that just as benzene was ini-
tially misclassified as a nongenotoxic car-
cinogen due to incomplete testing, so we
may find that TCDD is a genotoxic car-
cinogen. TCDD is a chemical that acts
through many mechanisms, and trying to
explain the overall biological activity of a
chemical by a single mechanistic model can
be misleading. Ifin vivo genetic monitoring
tests are to serve as accurate procedures for
detecting the effects of complete carcino-
gens, a battery of relevant assays must be
carried out concurrently in an exposed pop-
ulation. There are several complementary
procedures now available for human geno-
toxicity monitoring. Greater use of these
tests would provide a means to correctly
identify exposure to mutagenic carcinogens,
thus minimizing the erroneous classification
ofa carcinogen as nongenotoxic.
Biological Markers and
Genetic Monitoring
Biological markers are divided into three
major categories: exposure, effect, and sus-
ceptibility (8). Genetic monitoring is
mainly concerned with markers ofexposure
and effect, while genetic screening is con-
cerned with susceptibility. Markers ofexpo-
sure can include external exposure, which is
an environmental measurement of chemi-
cals or other agents presented to an organ-
ism, as well as internal exposure, a
measurement ofchemicals or their metabo-
lites that are present within the organism.
Measures ofinternal exposure include phar-
macokinetic data, such as biological half-
life, circulating peak, or cumulative dose. A
biologically effective dose is the amount of
material that can produce detectable effects
in critical subcellular, cellular, and tissue
targets. Markers ofeffect, such as genotoxi-
city, are responses of an organism that can
be related to health impairment or the
probability of health impairment (9).
Genotoxic effects can be detected by using
genetic monitoring procedures. Results of
these tests can be correlated with, and are
predictive of, cancer when analyzed in the
context of an exposed population. In the
evaluation of a population potentially
exposed to a carcinogen, it is best to use
both external and internal measurements of
exposure and markers ofeffects.
Peripheral lymphocytes are the cell
population ofchoice for most genetic mon-
itoring studies because they are readily
obtainable from a blood sample. One of
the major advantages in using circulating
lymphocytes is their contact with many
body tissues, thus providing a more inte-
grated measure of biological response to a
chemical exposure (10). After exposure to a
potential mutagen, reactive metabolites can
be derived either from the inherent meta-
bolic capacity ofthe lymphocytes, or, more
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probably, from reactive metabolites picked
up from other tissues such as the liver.
Adduct Formation
Many, if not most, carcinogens are elec-
trophilic chemicals that react with nucle-
ophilic sites of DNA resulting in covalent
reaction products (adducts). In addition to
the fact that most carcinogens form DNA
adducts, there are several characteristics of
adduct formation that would suggest that
the determination of adducts would be an
ideal procedure to use in genetic monitor-
ing. Studies in experimental animals have
shown a linear relationship between expo-
sure to an electrophile and the rate ofboth
DNA and protein adduct formation (11).
This has also been demonstrated in
humans exposed to ethylene oxide, and
propylene oxide, and individuals exposed
to ethylene from cigarette smoke (12).
Even trace amounts of adducts formed
from exogenous chemicals can be detected
with present methods. However, there are
several problems with adduct formation
studies that must be considered when uti-
lizing these procedures.
Although a linear relationship with
adduct formation has been observed with
many chemicals, nonlinear responses have
also been documented. One example is the
ethylating agent 4-(n-methyl-N-nitroso-
amino)-1-(3-pyridyl)-1-butanone. When
06-methylguanine adducts were measured
in rat lung after chronic exposure to this
chemical, a nonlinear dose-response was
observed (13). It should be emphasized
that the adduct level found in DNA at any
point following exposure is not determined
by the rate ofadduct formation alone, but
also involves adduct elimination and cell
turnover. Elimination is a function of the
stability of the adduct and the type and
nature of DNA repair processes (14).
Adduct frequency can also be reduced by
cell death or cells undergoing mitosis. In
the case of the N-nitrosamines, alkylated
adducts are formed at the N and 0 atoms
of the purine and pyrimidine bases, with
the 06-methylguanine adducts being a
major source for the development ofmuta-
tions. The efficiency of the repair enzymes
(06-alkylguanine-DNA alkyltransferases)
in replacing or selectively removing the o6
lesion is probably an important factor in
determining the cancer risk of individuals
exposed to N-nitrosamines (15).
A single chemical may form a variety of
different adducts, but not all of them will
lead to mutations (15,16). Since the
determination of adducts alone will not
indicate the fixation of a genetic lesion, it
should not be considered as a stand-alone
procedure in the context ofa genetic moni-
toring protocol. Studies with the potent
hepatocarcinogen methapyriline further
underscores the advisability of determining
adduct formation only in conjunction with
assays that are further down the continuum
that leads to cancer. Methapyriline failed to
induce the formation ofdetectable adducts
in L5178Ycells at doses that induced muta-
tions at the thymidine kinase locus (17).
Although the ability to measure trace
amounts ofan adduct can be considered an
advantage, the extreme sensitivity of these
procedures has often outstripped our abil-
ity to interpret what is measured. Workers
who are not knowingly exposed to ethylene
oxide have measurable amounts of
hydroxyethyl adducts in their hemoglobin
(18). The presence of these adducts in
non-exposed workers is an example of the
difficulty in interpreting results having to
do with adduct formation. The determina-
tion ofadducts therefore should be viewed
as a possible measure of exposure and
potential genomic damage. The sum total
of all adducts in a particular cell or cell
population does not necessarily indicate the
risk oftumor formation. The formation of
adducts is, however, ofvalue when viewed
in conjunction with assays that represent
events further along on the road to cancer.
Initial Genetic Damage
in Exposed Cells
The greatest opportunity for genetic moni-
toring is in the early stage in the neoplastic
process following the initial fixation of the
genetic lesion in exposed cells. At this
stage, we can employ a variety of proce-
dures that identify the ability ofthe chemi-
cal to induce genetic lesions that can
survive repair processes. A fundamental
event in the carcinogenesis process, induc-
tion of heritable genetic damage, has been
satisfied. Genetic lesions can be detected in
easily available lymphocytes, but the lesions
are not necessarily tissue-specific. In later
stages in the neoplastic process, genetic
alterations in the progeny of initiated cells
tend to be increasingly localized in specific
tissues and organs. Obtaining cells from
potentially affected tissues or organs would
be difficult and sometimes not possible. By
using available lymphocytes, several of the
most valuable procedures for genetic moni-
toring can be applied during or soon after
exposure at a very early stage in the neo-
plastic process. Both point mutations and
cytogenetic damage can be determined.
The hprtmutant lymphocyte assay and gly-
cophorin A assay are two tests available for
determining somatic cell mutations and
cytogenetic assays that can be used to
include chromosome aberration studies
and the micronucleus test, as well as the
sister chromatid exchange (SCE) assay.
The HprtAssay
The hypoxanthine-phosphoribosyl-trans-
ferase (hprt) assay (19) is one of the most
fully developed tests for somatic cell muta-
tions in humans. This test identifies and
selects mutant cells in a single step by tak-
ing advantage of the biochemical pathway
by which cells synthesize DNA. DNA is
synthesized in two ways: either from
nucleotide bases de novo or from bases recy-
cled from degraded DNA (the salvage
pathway). HPRT is one of the enzymes
involved in the salvage pathway. The assay
selects for mutant cells having a nonfunc-
tioning hprtgene. The selective agent used
in the hprt assay is 6-thioguanine, a toxic
purine analog. When incorporated into
DNA, 6-thioguanine causes cell death.
Mutant cells, lacking HPRT, are unable to
incorporate the 6-thioguanine. Thus, they
survive in short-term culture and can be
efficiently detected by either an autoradi-
ographic or clonal assay. Mutants can be
detected since the hprt locus is on the X
chromosome. Only one functional copy of
the hprtgene is present in the cells ofsub-
jects of either sex. Several studies have
demonstrated the feasibility of this assay
for determining effects of exposure to
mutagens-carcinogens, including the ability
to discriminate between cigarette smokers
and nonsmokers (20,21).
SisterChromatidExchanges
SCEs occur through mechanisms that
involve DNA breakage and rejoining. Sister
chromatids can exchange seemingly identi-
cal segments ofDNAwithout known alter-
ations of cell viability or function (22).
SCE studies have been used in a variety of
in vitro and in vivo assays to determine
exposure to mutagenic-carcinogenic
agents. The exact mechanism ofthe forma-
tion ofSCEs is not known, although repli-
cation or recombination models have been
proposed (23). The recombinant model is
based on chromatid exchange as part of a
post-replication repair process (24,25).
The replication model involves recombina-
tion during DNA replication (26,27). The
processes that lead to the formation of
SCEs are believed to be distinct from those
that lead to chromosome aberrations (28).
Chromosome aberrations can result
from exposure to chemicals that can induce
either single- or double-strand breaks. In
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contrast, SCEs can best detect chemicals
that have covalent interactions with DNA.
Therefore, ionizing radiation and carcino-
gens such as bleomycin, which are readily
detected by chromosome aberration stud-
ies, do not produce SCE. Although SCE
may be a sensitive indicator for the pres-
ence ofcertain carcinogenic agents, the lack
of understanding of the basis of the SCE
induction, its failure to detect some known
carcinogens, and the lack of relationship
with specific health effects limits its utility.
If only a single cytogenetic procedure is
selected for genetic monitoring, it should
not be the SCE assay.
TheMicronucleusTest
Micronuclei consist of small fragments of
DNA that can be detected in the cytoplasm
of a daughter cell after cell division.
Micronuclei are formed by the action of
chemicals that induce chromosome breaks
or agents that cause damage to the spindle
apparatus (29). The types of genetic dam-
age that contribute to the formation of
micronuclei include: damage to kineto-
chore proteins that affect the centromere
and spindle apparatus and lead to unequal
chromosome distribution at anaphase, and
unrepaired DNA strand breaks that result
in acentric chromosome fragments. Studies
using kinetochore antibodies to identify
whole chromosomes suggest that approxi-
mately 50% of spontaneously occurring
micronuclei are the consequence of whole
chromosome loss and the rest presumably
are derived from acentric chromosome
fragments (30-32). Micronucleus assays in
humans can be conducted using peripheral
blood lymphocytes (33), erythrocytes from
splenectomized individuals (34), and exfo-
liated cells from the buccal mucosa or the
urinary tract (35). A relatively new tech-
nique for use with lymphocytes is the
cytokinesis-block micronucleus assay. In
this procedure, cytochalasin-B is employed
to stop dividing cells from performing
cytokinesis; thus allowing cells that have
completed one nuclear division to be rec-
ognized by their binucleate appearance.
This assay is more accurate and more sensi-
tive than the conventional lymphocyte
micronucleus assay which does not distin-
guish between dividing and non-dividing
cells (36). The micronucleus test is a valu-
able complement to the chromosome aber-
ration procedure and is comparatively easy
and inexpensive to perform. However, the
specific location of the chromosome dam-
age cannot be determined, and rearrange-
ments will not be detected.
Chromosome Aberration
Assay
This assay is frequently used to document
the induction ofchromosome breakage and
rearrangement resulting from exposure to
mutagens and carcinogens. A variety of
studies have been performed to indicate
that chromosome aberrations are the con-
sequence of DNA damage and abnormal
repair and replication. For example,
Natarajan et al. (37) used Neurospora
endonuclease to convert radiation-induced
single-strand DNA breaks into double-
strand breaks in irradiated cells and
observed a significant increase in chromo-
some aberrations. They concluded that
DNA double-strand breaks are the ultimate
lesions for the formation of chromosome
aberrations. By incubating damaged cells in
the presence of a DNA repair inhibitor,
cytosine arabinoside, Preston (38) was able
to demonstrate that chromosome aberra-
tions can be caused by abnormal DNA
repair processes. Using the premature chro-
mosome condensation technique to reveal
chromosome aberrations in different phases
of the cell cycle, Sognier and Hittelman
(39) showed that mitomycin-C-induced
chromatid breaks are the consequence of
incomplete DNA replication. Chromosome
aberrations can, therefore, be caused by
many different types of hazardous agents,
and by different mechanisms. Ionizing
radiation and radiomimetic chemicals (e.g.,
bleomycin and neocarcinostatin) cause the
formation of chromosome-type aberra-
tions, while the majority of chemicals
induce chromatid-type aberrations. Thus,
the chromosome aberration assay can be
used as a general biological marker for doc-
umentation of exposure to potentially haz-
ardous agents. Since chromosome
abnormalities are frequently observed in
cancer cells, in spontaneously aborted
fetuses, and in abnormal newborns
(40-42); the detection of chromosome
aberrations in an exposed population is
viewed as a pathobiological response to
exposure, and as an indication ofpotential
long-term health consequences.
It is well known that most of the
detectable chromosome aberrations in the
standard cytogenetic assay are lesions that
are incompatible with cell survival. The
long-term health consequences are, there-
fore, caused by the damaged cells that sur-
vive. For a precise determination of health
risk, it is often necessary to identify abnor-
mal cells that are capable of surviving and
replicating. These abnormal cells may be
identified by the use ofchromosome band-
ing analysis to detect viable cells having
balanced chromosome translocations. In
addition to the use ofbanding procedures,
chromosome rearrangements can also be
detected by using fluorescenated antibodies
that can recognize specific chromosomal
DNA sequences (43-45).
Chromosome/Genetic Instability
Although conventional cytogenetic and
gene mutation studies are established pro-
cedures for detecting exposure to a number
of carcinogenic agents, other relevant bio-
logical effects may not be documented by
these procedures. The interaction of car-
cinogenic metabolites with cellular macro-
molecules may alter the normal cell
processes and may not be detected by the
standard genetic assays.
Evidence suggests that carcinogen-
exposed, potentially committed cells are
unable to stabilize (or normalize) their
genomes (46,47). One ofthe mechanisms
to explain this phenomenon is that these
cells are unable to repair additional DNA
damage correctly. In other words, these
cells may be much more susceptible to the
induction of damage from exogenous and
endogenous sources than nonexposed and
noncommitted cells. We have developed a
DNA repair assay (challenge assay) to eluci-
date this phenomenon (48). In this assay,
lymphocytes from subjects exposed in vivo
to carcinogens are subsequently adminis-
tered gamma-rays in vitro in the GO or G1
phase of the cell cycle. These cells are,
therefore, challenged to repair the radia-
tion-induced DNA damage. Cells previ-
ously exposed to toxic pollutants may have
exposure-induced DNA repair deficiency
and may have trouble repairing the radia-
tion-induced (challenge) DNA damage.
They will therefore have more chromoso-
mal abnormalities than nonexposed cells in
our challenge assay. In a study of cigarette
smokers compared to nonsmokers, we
showed that smokers had a significantly
higher frequency ofchromosome transloca-
tions than nonsmokers in the challenge
assay (49). We have also shown that mito-
mycin-C (a DNA cross-linking agent) and
nickel (a nongenotoxic carcinogen) can sig-
nificantly enhance the frequency of radia-
tion-induced chromosome aberrations
(48). This phenomenon is observed even
when nonclastogenic doses of mitomycin-
C or nickel were used. The cytogenetic
fidelity repair assay (challenge assay) is a
useful addition to the battery of tests that
are available for detecting biological effects
that are relevant to the development ofcan-
cer and other long-term health problems.
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Initiatd orPredisposed Cell;
Diminishing Opportunity
for GeneticMonitoring
The initiated cell and the immediate prog-
eny of the initiated cell exhibit both an
altered responsiveness to their microenvi-
ronment and a selective clonal advantage
when compared to surrounding cells (50,
51). These changes are believed to occur
more likely in cells having genetic instabil-
ity. Exposure to agents that are tumor pro-
moters results in proliferation and/or
survival of the initiated cell to a greater
extent than normal cells. Continuing cell
proliferation enhances the probability of
additional genetic errors including endoge-
nous mutations to accumulate in the
expanding population of these initiated
cells. Although clinical cancer can theoreti-
cally result from a genetic alteration in a
single cell (the clonal origin ofcancer) and
from exposure to any amount ofa carcino-
gen (i.e., no exposure threshold), the prob-
ability of a subpopulation of initiated cells
converting to detectable malignancy can be
substantially increased by the further expo-
sure of initiated cells to DNA-damaging
agents. The emerging cell population may
consist of cells with activated protoonco-
genes and/or inactivated tumor suppressor
genes that affect regulation of growth and
differention pathways. Cells having these
specific genetic alterations are increasingly
localized in specific organs and tissues. This
localization increases the difficulty of
obtaining suitable materials for genetic
monitoring.
Molecular analysis ofmutationally acti-
vated protooncogenes (e.g., ras) in animal
models ofcarcinogenesis supports the con-
cept ofa mutational spectrum that is char-
acteristic of specific types of mutagenic
agents. For example, the mutations found
in activated ras oncogenes that are associ-
ated with tumors ofrodents exposed to the
methylating N-nitroso compounds are
mainly caused by methylation ofdeoxygua-
nine at the o6 position followed by mis-
pairing with thymine during DNA
synthesis. The type of mutation leading to
activation ofprotooncogenes and/or inacti-
vation oftumor suppressor genes may also
be indicative of the tissue in which the
malignancy is found (52). Following a
period of genetic instability (gene amplifi-
cation and altered expression, change in
chromosome number and structure), the
resultant cell population may contain cells
with specific activated oncogenes or inacti-
vated suppressor genes. However, at this
stage, the transformed cells may be local-
ized in specific tissues, and positive assays
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Figure 2. Specific stages in the neoplastic process that offers the greatest opportunity for genetic monitoring.
may be mostly indicative of clinical out-
come rather than being useful in preventive
genetic monitoring.
TheNarrowWmdowofOpportunity
forGeneticMonitoring
In Figure 2, we have indicated the specific
stage in the neoplastic process that offers
the greatest opportunity for genetic moni-
toring. The earliest significant biological
response that indicates unrepaired genetic
damage occurs after adduct formation. At
this stage cytogenetic studies as well as
assays for point mutations can be con-
ducted. As we move further along the con-
tinuum to cancer, clonal expansion of
mutated cells occurs in the tissue in which
the tumor will form. This poses difficulties
for obtaining samples for analysis.
Analyzing tissue to detect cells that contain
activated protooncogenes or inactivated
suppressor genes would further document
an adverse response from exposure to car-
cinogens; but, as previously discussed, this
may be ofgreater value for indicating dini-
cal outcome rather than for genetic moni-
toring. With a few notable exceptions (53),
the window of opportunity for genetic
monitoring is the period shortly after expo-
sure (or during chronic exposure) when
genetic damage has occurred and where cir-
culating lymphocytes can be used to detect
this damage.
Limitations ofCancerEpidemiological
Studies Necessitates Genetic
Monitoring
In characterizing the need and value of
genetic monitoring, one must also consider
the alternatives presently available for
determining the biological consequences of
exposure to carcinogenic-mutagenic agents.
The most definitive procedure for detect-
ing adverse health effects is the conven-
tional epidemiologic study, a procedure
focused on the final disease outcome. In
the area ofchronic diseases, however, tradi-
tional epidemiologic studies often lack sen-
sitivity and thus should not be considered
our primary method for detecting harmful
exposures to hazardous substances.
Furthermore, the prediction made in 1982
(2), that few human epidemiologic studies
of exposure to known animal carcinogens
would be carried out, seems to have been
accurate. A survey of industry concerning
epidemiologic studies on 73 animal car-
cinogens identified by the International
Agency for Research on Cancer (IARC)
found that epidemiologic data were lacking
for approximately 90% of the animal car-
cinogens and that industry anticipated few
further studies (54). In addition to finan-
cial considerations, the following were
some of the reasons for not considering
epidemiological studies: a) insufficient time
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lapse since beginning ofexposure, b) small
work force, c) mixed exposure, and d) short
exposure period for each chemical (52).
In examining the reasons given for not
initiating epidemiologic studies, one is
struck by the fact that biological monitoring
methods, such as cytogenetic and somatic
cell mutation studies, would overcome the
difficulties cited. The cost of biological
monitoring is a fraction ofthe cost oftypical
epidemiologic studies. The outcome is seen
concurrently with exposure, thus overcom-
ing the need to wait for the final disease out-
come (which frequently results in death).
The effect of mixed exposures is integrated
into the overall response that is detected,
and the number of subjects needed for a
conclusive genotoxicity monitoring study is
minimal (approximately 50 to 100) in com-
parison to epidemiologicstudies that may
involve thousands ofsubjects.
Studieswith 1,3 Butadiene
Example ofanIntegrated Genetic
MonitoringProgram
1,3-Butadiene is a high-volume chemical
used in the manufacture of synthetic rub-
ber (styrene-butadiene rubber or polybuta-
diene rubber) and of thermoplastic resin.
The annual production volume of this
chemical is approximately 12 billion
pounds worldwide with 3 billion pounds
produced in the United States (55,56).
Approximately 65,000 workers are poten-
tially exposed to 1,3-butadiene (57).
Limited initial toxicologic studies indicated
a low order of toxicity (58). Subsequent
studies, however, indicate that this chemi-
cal is a potent multispecies, multiorgan car-
cinogen (59). It is found to be
carcinogenic in B63F1 mice with the low-
est concentration tested (6.25 ppm) (59).
The conversion of 1,3-butadiene to the
reactive metabolites 1,2-epoxy-3-butane
and dieposidebutane have been identified
in rats and mice (60).
Although metabolic and pharmacoki-
netic differences have been identified in dif-
ferent species after exposure to the chemical,
the interpretation of the data as related to
human exposure is questionable. An analysis
of available epidemiological studies, how-
ever, support the conclusion that 1,3-buta-
diene is ahuman carcinogen (59).
Genetic monitoring ofworkers exposed
to this chemical would determine ifcurrent
exposure levels produce detectable genetic
damage and further indicate the sensitivity
ofhumans to this chemical. At the present
time several laboratories are carrying out an
investigation with a population ofworkers
exposed on average to 1-3 ppm of butadi-
ene. The protocol includes determining
adduct formation, induction of hprt vari-
ants, chromosomal aberrations, DNA
repair problems using a challenge assay, sis-
ter chromatid exchanges, and urinary
metabolites. The different assays are con-
ducted using the same population, thus
increasing the sensitivity of the genetic
monitoring. Furthermore, the biological
data can be correlated with the metabolic
information. The initial results ofthe pilot
study (61) indicate that present exposure
levels produced an increase in hprtvariants
and that this increase can be correlated with
a butadiene derived urinary metabolite.
The present genetic monitoring studies
with 1,3-butadiene may serve as a model for
future studies. A high-volume industrial
chemical was selected and workplace expo-
sure measurements were available. Critical
indices of exposure and biological effects
will be determined. The initial results ofthe
pilot study have already answered critical
questions as to the potential hazard of this
chemical under current exposure conditions.
Conclusion
With better understanding of the multi-
stage carcinogenic process, we see a win-
dow ofopportunity for genetic monitoring.
Since populations at risk are exposed to
many hazardous agents, which may operate
via different mechanisms, it is necessary to
use assays that can detect the sum total of
genetic damage. Evidence is presented to
emphasize that the most critical stages in
the neoplastic process for genetic monitor-
ing are at the stages in the process that
occur after formation of the genetic lesion
leading to gene and chromosomal muta-
tions. Pregenomic damage studies (adduct
formation) will not indicate the extent of
repair or subsequent genetic damage. On
the other hand, as we proceed on the path
to cancer, later events may occur in non-
accessible target organs. Another criteria for
selecting the best mix ofassays is to utilize
only those procedures where the result can
be readily interpreted. The SCE assay is an
example of an assay where results are not
readily understood, therefore, it cannot be
used as a stand alone assay. The ideal
approach for population monitoring and
subsequent risk assessment, therefore
would utilize a battery of relevant biologi-
cal procedures carried out concurrently
utilizing readily available peripheral lym-
phocytes. The challenge assay, cytogenetic
studies, and gene mutation assays, when
used on the same population, form the
basis of an optimum study. In addition to
biological indicators, it is desirable to deter-
mine critical metabolites, which can then
be correlated with the biological assays.
Adduct formation and SCE studies, inte-
grated into a comprehensive protocol, may
offer additional supporting information for
risk determination.
An example ofa model genetic monitor-
ing study is the present ongoing interna-
tional collaborative study with workers
exposed to low levels of butadiene. In this
comprehensive study, critical biological end-
points including gene mutations, and chro-
mosome abnormalities are being studied. In
addition, the challenge assay as well as ancil-
lary studies including SCE and adduct for-
mation are being conducted with the same
population. The biological studies are also
being correlated with urinary metabolites.
The present butadiene study illustrates what
can be accomplished with these techniques
in evaluating low dose chronic exposure to a
chemical or chemical mixtures.
Properly conducted genetic monitoring
studies are the ideal approach for monitor-
ing population exposed to suspected car-
cinogenic agents. These studies will
produce relevant information in our target
species-man-and can be used for risk
assessment. The need to utilize genetic
monitoring in both the occupational and
nonoccupational setting is readily under-
stood with the realization that the alterna-
tive to genetic monitoring is the costly,
time consuming and insensitive traditional
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